https://smallcaps.com.au/us-farm-bill-legalise-commercialise-indu...

https://smallcaps.com.au/us-farm-bill-legalise-commercialise-industrial-hemp/

Market share of Elixinol ranked 5th in hemp derived CBD market. CW hemp, CV science and Medical marijuana are top 3 with close market share, but their market caps are so different, over 800m, 440m, and 230m, in USD. I understand that Medical marijuana is still making losses, so the valuation is relative low. However, CV sciences's profit (3m) is higher than CW hemp (2m). Can anyone explain why CW hemp is almost two times the market cap of CV sciences? 

Considering Elixinol's valuation of 180m with probably less than 1m profit, I think Elixinol is quite fairly valued or marginally undervalued compared to CV sciences and Medecal marijuana. The good thing is that Elixnol is catching up in the 3rd quarter. With the commissioning of new facility, I hope Elixinol can take the opportunity to grab more market share.